

Sterols and Terpenoids from *Melia azedarach*Qin-Gang Tan,^{†,‡} Xiao-Ning Li,[†] Hao Chen,^{†,§} Tao Feng,[†] Xiang-Hai Cai,[†] and Xiao-Dong Luo^{*,†}

State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, People's Republic of China, Guilin Medical College, Guilin 541004, People's Republic of China, and Kunming University of Science and Technology, Kunming 650093, People's Republic of China

Received January 22, 2010

Three new sterols (**1–3**) including an unprecedented ring A-secosterol natural product (**1**), five new terpenoids (**4–8**), and 15 known compounds were isolated from the bark of *Melia azedarach*. Their structures were elucidated by means of spectroscopic data, and the structure of **1** was confirmed by X-ray crystallography.

Melia azedarach Linn. (Meliaceae), widely distributed in southern districts of the Yellow River in China,¹ has been used as a biopesticide.² The bark of *M. azedarach* has been used as an insect repellent, for threadworm, and as a therapeutic medicine for tinea imbricata in the Chinese Pharmacopoeia.³ The plant is known to contain sterols, terpenoids, protolimonoids, and limonoids and to show analgesic, anticancer, antiviral, antimalarial, antibacterial, and antifeedant activities.^{4,5} Now we describe the isolation and structure elucidation of three new sterols (**1–3**), four new tirucallane triterpenoids (**4–7**), and a new tetranortriterpenoid (**8**) from an ethanol extract of *M. azedarach* bark.

Results and Discussion

Fractionation of a 90% ethanol extract of *M. azedarach* bark by repetitive chromatographic separation yielded eight new compounds (**1–8**). Compound **1** was obtained as colorless needles (MeOH) and possessed the molecular formula C₂₁H₃₀O₅ by HRESIMS, indicating seven degrees of unsaturation. The IR spectrum showed absorption peaks at 3432 (OH), 1729 (C=O), and 1631 cm⁻¹ (C=C), respectively. UV absorption at λ_{max} 258 nm (log ε 3.79) was consistent with a five-membered α,β-unsaturated ketone chromophore.⁶ The signals at δ_H 11.98 (2H, br s) in the ¹H NMR spectrum and corresponding signals at δ_C 174.4 (s) and 172.5 (s) in the ¹³C NMR spectrum indicated the presence of two carboxyl groups. Signals of a ketone group (δ_C 207.7, s) and a trisubstituted double bond (δ_C 148.2, 129.0) were also presented. Therefore, **1** was deduced to be a ring-secosterol on the basis of the three remaining degrees of unsaturation and the signals of three methyl groups and two high-fielded quaternary carbons in the ¹³C NMR spectrum. In the HMBC spectrum, correlations of δ_C 172.5 (C-2) with δ_H 2.23 (H-1) and 0.76 (H-19) and of δ_C 174.4 (C-3) with δ_H 2.51 (H-4) suggested the C-2/C-3 bond was cleaved to form two carboxyl groups. Moreover, correlations of δ_C 148.2 (C-17) with δ_H 0.84 (H-18) and 1.98 (d, H-21) and of δ_C 207.7 (C-16) with δ_H 5.71 (q, H-20) and 2.04 (H-15) in the HMBC spectrum indicated that the ketone group at C-16 was conjugated with the double bond at C-17/C-20. The α-orientation of H-5 was suggested by correlation of δ_H 2.05 with δ_H 1.37 (H-9) and δ_H 1.28 (H-14) in the ROESY spectrum (Figure 1). Thus, compound **1** was elucidated as 2,3-seco-dicarboxylpregn-17-en-16-one. Since the ring A-secosterol was unusual, an X-ray diffraction study was performed to confirm the structure (Figure 2).

Compound **2** (C₂₁H₃₂O₅) was obtained as colorless needles. The IR spectrum showed absorptions at 3444 cm⁻¹ (OH) and 1639 cm⁻¹

(C=C). Signals of two high-field quaternary carbons and an *O*-methylene group (δ_C 63.0) in the ¹³C NMR spectrum, along with a singlet methyl and a triplet methyl in the ¹H NMR spectrum, suggested that **2** was a pregnane derivative. The ¹³C NMR spectrum also showed signals of a ketone group (δ_C 221.8), a trisubstituted double bond (δ_C 143.8 and 128.3), and three oxymethine groups (δ_C 68.1, 78.4, and 79.2) (Table 1). The *O*-methylene was assigned to C-18 by correlations of δ_C 63.0 with δ_H 1.78 (H-17) and of δ_C 47.4 (C-13) with δ_H 3.94, 3.54 (H-18) in the HMBC spectrum. Correlation of δ_C 221.8 with δ_H 1.78 (H-17) in the HMBC spectrum assigned C-16 as a ketone. The correlations of δ_H 3.20 (1H, dd, *J* = 9.6, 3.8 Hz) with δ_H 4.17 (1H, d, *J* = 3.8 Hz) and with δ_H 3.99 (1H, d, *J* = 9.6 Hz) in the ¹H–¹H COSY spectrum indicated three adjacent oxymethine groups. By comparing the chemical shifts and coupling constants with those of 2β,3β,4β-trihydroxypregnan-16-one and of 2α,3α,4β-trihydroxypregnan-16-one,⁷ compound **2** was assumed to have a 2α,3β,4β-trihydroxy orientation, which was further supported by correlations of δ_H 3.99 (H-2) with δ_H 1.29 (H-19) in the ROESY spectrum (Figure 1). The double bond was assigned at C-5/C-6 on the basis of the correlations of δ_C 79.2 (C-4) and δ_C 33.2 (C-7) with δ_H 5.70 (H-6) and of δ_C 143.8 (C-5) with δ_H 4.17 (H-4) and δ_H 1.29 (H-19) in the HMBC spectrum. Thus, compound **2** was elucidated as 2α,3β,4β,18-tetrahydroxypregn-5-en-16-one.

Compound **3** had the molecular formula C₂₈H₄₆O₄ on the basis of the quasimolecular ion peak at *m/z* 469.3300 [M + Na]⁺. The IR spectrum showed absorption peaks at 3415 cm⁻¹ (OH) and 1639 cm⁻¹ (C=C). The difference between compound **3** and 3β,16β,20-trihydroxyergosta-5,24(28)-diene⁸ in the ¹³C NMR spectrum (Table 1) was the presence of an oxymethine group in the former instead of a methylene group in the latter, indicating four OH groups in **3**. The additional OH was attached to C-22 on the basis of correlations of δ_H 3.82 (22-OH) with δ_H 1.76 and 2.19 (H-23) in the COSY spectrum and correlations of δ_C 78.6 (C-20) and δ_C 37.5 (C-23) with δ_H 3.82 (22-OH) in the HMBC spectrum (Figure 1). Unlike 3β,16β,20-trihydroxyergosta-5,24(28)-diene, the NOE correlations of δ_H 3.24 (H-3) with δ_H 0.94 (H-19) in the ROESY spectrum indicated the α-orientation of OH-3 in **3**. The structure was otherwise identical to that of 3β,16β,20-trihydroxyergosta-5,24(28)-diene by detailed analysis of the ¹H and ¹³C NMR, HSQC, HMBC, ¹H–¹H COSY, and ROESY spectra of **3**. Thus, compound **3** was elucidated as 3α,16β,20,22-tetrahydroxyergosta-5,24(28)-diene.

Compound **4** had the molecular formula C₃₀H₄₄O₄ by HRESIMS, indicating nine degrees of unsaturation. The UV absorption bands at λ_{max} 244 nm (log ε 4.74) indicated an α,β-unsaturated ketone chromophore,⁹ and IR absorptions were present at 3442 (OH), 1787 (γ-lactone), and 1642 cm⁻¹ (conjugated double bond), respectively.¹⁰ The ¹H NMR spectrum of **4** showed signals of two trisubstituted double bonds (δ_H 5.69, 5.09) and two geminal methyl groups (δ_H 1.61, 1.69) attached to an olefinic carbon (Table 2).


* To whom correspondence should be addressed. Tel: +86 871 5223177. Fax: +86 871 5150227. E-mail: xdluo@mail.kib.ac.cn.

[†] Kunming Institute of Botany, Chinese Academy of Sciences.

[‡] Guilin Medical College.

[§] Kunming University of Science and Technology.

Chart 1



The ^{13}C NMR spectrum displayed signals of two carbonyl groups (δ_{C} 200.8, 180.1), two trisubstituted double bonds (δ_{C} 167.3, 132.9, 124.6, 123.2), and two oxymethine groups (δ_{C} 81.6, 76.6) (Table 3). The remaining degrees of unsaturation were ascribed to five rings. In the HMBC spectrum, correlations of δ_{C} 45.2 (C-20) with δ_{H} 4.15 (H-16) and of δ_{C} 180.1 (C-21) with δ_{H} 2.44 (H-20) (Figure 1) indicated the presence of a 20,16-olide moiety as in sendanolactone from the same species.⁹ The difference between the two compounds was the presence of an OH at C-3 in **4** instead of the ketone group in sendanolactone, which was supported by correlations of δ_{C} 76.6 (C-3) with δ_{H} 1.25 (H-28) and δ_{H} 1.13 (H-29) in the HMBC spectrum (Figure 1). The broad singlet of H-3 suggested an α -orientation of the OH group. This assignment was supported by correlations of δ_{H} 3.36 (H-3) with δ_{H} 1.13 (H-29) and δ_{H} 1.27 (H-30) in the ROESY spectrum. The remaining structure was identical to that of sendanolactone by analysis of the ^1H and ^{13}C NMR, HSQC, HMBC, ^1H - ^1H COSY, and ROESY spectra of **4**. Thus, compound **4** was 3 α -hydroxytirucalla-7,24(25)-dien-6-oxo-21,16-olide.

Compound **5** had the molecular formula $\text{C}_{30}\text{H}_{42}\text{O}_4$ and IR absorptions of carbonyl groups at 1777 and 1707 cm^{-1} . The ^1H NMR spectrum exhibited six methyl groups, one of which was

attached to an olefinic carbon, and three olefinic protons (Table 2). The ^{13}C NMR spectrum showed signals of three carbonyl groups (δ_{C} 216.4, 201.1, 180.5), a trisubstituted double bond (δ_{C} 118.5, 143.3), and a terminal double bond (δ_{C} 125.1, 144.2) (Table 3). In the HMBC spectrum, correlations of δ_{C} 180.5 (C-21) with δ_{H} 1.84, 2.05 (H-22) and δ_{H} 2.49 (H-20) suggested a 20,16-olide moiety as in kulactone^{10,11} (Figure 1). Correlations of δ_{C} 125.1 (C-26) with δ_{H} 1.86 (H-27) and of δ_{C} 201.1 (C-24) with δ_{H} 1.86 (H-27) and δ_{H} 6.01 (H-26a) in the HMBC spectrum indicated that the ketone group was conjugated with the terminal double bond. The chiral carbons in rings A–D and the lactone ring were identical to those of kulactone by analysis of the ^1H and ^{13}C NMR, HSQC, HMBC, ^1H - ^1H COSY, and ROESY spectra of **5**. Thus, compound **5** was elucidated as tirucalla-7,25(26)-diene-3,24-dione-21,16-olide.

Compound **6** showed a quasimolecular ion peak at m/z 533.2677 $[\text{M} + \text{Cl}]^-$ in the negative HRESIMS, indicating the molecular formula $\text{C}_{30}\text{H}_{42}\text{O}_6$ and consistent with 10 degrees of unsaturation. UV absorptions at λ_{max} 244 nm ($\log \epsilon$ 4.79) suggested an α,β -unsaturated ketone chromophore as in **4**. The ^1H NMR spectrum showed signals of three olefinic protons and a proton attached to an oxymethine carbon (Table 2). In comparison to sendanolactone,¹⁰ the ^1H and ^{13}C NMR data of **4** and **6** were almost the same except




Figure 1. Key HMBC ($^{13}\text{C} \rightarrow ^1\text{H}$) and selected ROESY (dashed arrows) correlations for compounds **1**–**5**, **7**, and **8**.




Figure 2. ORTEP diagram of **1**.

for signals of the side chain. A signal at δ_{H} 7.83 (1H, s) in the ^1H NMR spectrum and the corresponding quaternary carbon (δ_{C} 81.8) in the ^{13}C NMR spectrum, together with two remaining oxygen atoms in compound **6**, indicated that **6** must have a hydroperoxy group. This assignment was supported by the similarity of the spectroscopic data of **6** to those of meliastatin 3,12 regarding the side chain. Thus, the double bond in **6** was deduced to be at C-23/C-24, and the hydroperoxy group was placed at C-25 by comparison of its data with the two aforementioned compounds. Consequently, compound **6** was elucidated as 25-hydroperoxytirucalla-7,23(24)-dien-3,6-dien-21,16-olide.

Compound **7** ($\text{C}_{30}\text{H}_{44}\text{O}_4$) had IR absorption peaks at 3442 (OH), 1737 and 1705 ($\text{C}=\text{O}$), and 1630 cm^{-1} ($\text{C}=\text{C}$), respectively. The ^{13}C NMR spectrum exhibited signals of two ketone groups (δ_{C} 216.6, 181.7) and two trisubstituted double bonds (δ_{C} 144.3, 140.1, 121.7, 118.8). Considering the nine degrees of unsaturation and the aforementioned functionalities, **7** was deduced to have five rings. Comparing the spectroscopic data of **7** with those of 3,21-dioxotirucalla-7,24-dien-21,23-olide, 13 **7** showed an additional oxymethine signal instead of a methylene. Correlations of δ_{H} 4.28 (H-16) with δ_{H} 1.92 (H-17) and δ_{H} 2.10 (H-15a) in the ^1H - ^1H COSY spectrum positioned the OH at C-16, which was supported by correlations of δ_{C} 48.9 (C-14) and δ_{C} 41.1 (C-20) with δ_{H} 4.28 (H-16) in the HMBC spectrum (Figure 1). Correlation of δ_{H} 4.28 (H-16) with δ_{H} 0.84 (H-18) in the ROESY spectrum indicated the β -orientation of 16-OH. Thus, compound **7** was elucidated as 16 β -hydroxytirucalla-7,24(25)-dien-3-oxo-21,23-olide.

Compound **8** ($\text{C}_{32}\text{H}_{42}\text{O}_{13}$) showed IR absorption peaks for OH and carbonyl groups. The ^1H NMR, ^{13}C NMR, and DEPT spectra exhibited signals that were characteristic of meliacarpinin-type compounds (Tables 2 and 3). 14 Compared with 1-tigloyl-3,20-diacetylmethoxymeliacarpinin, 14 **8** was lacking signals of a tigloyl group. Instead, an additional methylene group in **8** corresponded to the 1-detigloyl derivative of 1-tigloyl-3,20-diacetylmethoxymeliacarpinin. This observation was supported by correlations of δ_{C} 33.2 (C-1) with δ_{H} 2.67 (H-5), δ_{H} 3.06 (H-9), and δ_{H} 3.96, 4.15 (H-19) in the HMBC spectrum. The coupling constants and chemical shifts of **8** at other protons and carbons were in good agreement with those of 1-tigloyl-3,20-diacetylmethoxymeliacarpinin. 14 Analysis of the ^1H and ^{13}C NMR, HSQC, HMBC, ^1H - ^1H COSY, and ROESY spectra of **8** indicated that the remaining structure was identical to that of 1-tigloyl-3,20-diacetylmethoxymeliacarpinin. Thus, compound **8** was 3,20-diacetylmethoxymeliacarpinin.

Table 1. ^1H NMR Data of Compounds **1**, a **2**, b and **3** a (δ in ppm and J in Hz)

position	1		2		3	
	δ_{H}	δ_{C} , mult.	δ_{H}	δ_{C} , mult.	δ_{H}	δ_{C} , mult.
1	2.23, dd (10.4, 4.3)	40.5, CH ₂	1.01, 2.02, m	46.6, CH ₂	0.93, 2.11, m	37.2, CH ₂
2		172.5, qC	3.99, t (9.6)	68.1, CH	1.35, 1.66, m	31.4, CH ₂
3		174.4, qC	3.20, dd (9.6, 3.8)	78.4, CH	3.24, m	70.0, CH
4	2.51, d (14.9)	35.3, CH ₂	4.17, d (3.8)	79.2, CH	2.12, m	42.8, CH ₂
5	2.05, m	39.9, CH		143.8, qC		141.3, qC
6	1.23, 1.56, m	26.9, CH ₂	5.70, t (2.0)	128.3, CH	5.25, d (5.6)	120.4, CH
7	1.39, 1.84, m	21.0, CH ₂	1.79, 2.16, m	33.2, CH ₂	1.42, 1.87, m	31.2, CH ₂
8	1.42, m	33.9, CH	1.99, m	31.6, CH	1.22, m	30.6, CH
9	1.37, m	47.8, CH	1.23, m	52.1, CH	0.86, m	49.7, CH
10		39.1, qC		38.9, qC		36.1, qC
11	1.19, 1.81, m	35.4, CH ₂	1.51–1.58, m	21.3, CH ₂	1.45, m	20.1, CH ₂
12	0.84, 1.53, m	31.0, CH ₂	1.50, 2.02, m	36.1, CH ₂	1.17, 2.03, m	40.0, CH ₂
13		42.6, qC		47.4, qC		42.2, qC
14	1.28, m	49.2, CH	1.70, m	51.8, CH	0.84, m	53.8, CH
15	2.04, m	39.7, CH ₂	2.13–2.18, m	39.8, CH ₂	1.19, 1.84, m	37.7, CH ₂
16		207.7, qC		221.8, qC	4.38, m	72.0, CH
17		148.2, qC	1.78, t (6.7)	64.2, CH	1.26, d (7.1)	56.2, CH
18	0.84, s	19.3, CH ₃	3.54, d (11.5), 3.94, d (11.5)	63.0, CH ₂	1.07, s	14.6, CH ₃
19	0.76, s	15.5, CH ₃	1.29, s	22.3, CH ₃	0.94, s	19.2, CH ₃
20	5.71, q	129.0, CH	1.51, 1.82, m	18.9, CH ₂		78.6, qC
21	1.98, d (5.6)	13.6, CH ₃	1.07, t (7.5)	14.2, CH ₃	1.05, s	19.9, CH ₃
22					3.83, s	73.8, CH
23					1.76, 2.19, m	37.5, CH ₂
24						153.9, qC
25					2.30, m	32.5, CH
26					0.99, d (3.5)	21.9, CH ₃
27					0.97, d (3.5)	21.7, CH ₃
28					4.73, 4.76, br s	107.9, CH ₂
-COOH	11.98					
3-OH					4.63, d (4.4)	
16-OH					5.95, d (3.4)	
20-OH					5.18, s	
22-OH					3.82, s	

a Spectra were recorded in DMSO- d_6 . b Spectrum was recorded in CD₃OD.

Table 2. ¹H NMR Data of Compounds 4–8 (CDCl₃, δ in ppm and *J* in Hz)

position	4	5	6	7	8
1	1.35, m	1.43, 1.95, m	1.73, 1.99, m	1.41, 1.95, m	1.34, 1.58, m
2	1.70, 1.98, m	2.28, 2.79, m	2.35, 2.77, m	2.08, 2.73, m	1.78–1.86, m
3	3.36, br s				4.91, t (2.6)
5	2.57, s	1.73, m	2.46, s	1.68, m	2.67, d (12.8)
6		2.14, m		2.09, m	3.89, dd (12.6, 2.8)
7	5.69, br s	5.33, t (3.0)	5.80, br s	5.33, t (2.8)	4.26, d (2.7)
9	3.04, m	2.49, dd (12.7, 6.3)	2.96, m	2.28, m	3.06, s
11	1.60, 1.99, m	1.58–1.71, m	1.77, 1.96, m	1.58–1.62, m	
12	1.81, 1.98, m	1.74, m	1.69, 1.88, m	1.42, 1.79, m	
15	1.75, 2.33, m	1.72, m	1.85, 2.38, m	1.75, 2.10, m	4.14, s
16	4.15, ddd (10.2, 10.2, 7.8)	4.16, ddd (10.8, 10.2, 7.7)	4.22, ddd (11.8, 10.3, 7.7)	4.28, dd (8.8, 5.5)	1.82, 2.06, m
17	2.14, m	2.14, m	2.19, m	1.92, m	2.97, d (5.9)
18	0.98, s	0.96, s	0.99, s	0.84, s	1.37, s
19	0.87, s	1.02, s	1.12, s	0.99, s	3.96, d (8.5); 4.15, d (8.5)
20	2.44, m	2.49, m	2.45, m	2.77, m	
21					5.67, s
22	1.51, m	1.84, 2.05, m	2.47, m	2.10–2.19, m	5.41, d (3.0)
23	2.05, 2.13, m	2.95, t (5.4)	5.68, ddd (15.8, 7.9, 6.5)	5.25, m	6.42, d (3.0)
24	5.09, m		5.64, br, t (15.8, 5.7)	5.29, d (3.0)	
26	1.61, s	6.01, 5.79, br s	1.32, s	1.74, s	
27	1.69, s	1.86, br s	1.34, s	1.72, s	
28	1.25, s	1.04, s	1.37, s	1.24, s	3.45 (d, 7.5); 3.51 (d, 7.5)
29	1.13, s	1.11, s	1.38, s	1.09, s	0.97, s
30	1.27, s	1.24, s	1.36, s	1.01, s	1.49, s
25-OOH			7.83, s		
11-OCH ₃					3.42, s
12-OCH ₃					3.82, s
CH ₃ CO-					2.09, s
CH ₃ CO-					2.10, s

Table 3. ¹³C NMR Data of Compounds 4–8 (CDCl₃, δ in ppm and *J* in Hz)

position	4	5	6	7	8
1	31.0, CH ₂	38.2, CH ₂	37.3, CH ₂	38.4, CH ₂	33.2, CH ₂
2	24.3, CH ₂	34.8, CH ₂	33.9, CH ₂	34.8, CH ₂	24.8, CH ₂
3	76.6, CH	216.4, qC	214.5, qC	216.6, qC	71.1, CH
4	39.3, qC	47.8, qC	47.1, qC	47.9, qC	42.3, qC
5	60.7, CH	52.5, CH	65.7, CH	52.3, CH	39.3, CH
6	200.8, qC	24.3, CH ₂	197.9, qC	24.2, CH ₂	71.7, CH
7	124.6, CH	118.5, CH	124.6, CH	118.8, CH	83.3, CH
8	167.3, qC	143.3, qC	167.6, qC	144.3, qC	51.9, qC
9	49.7, CH	47.7, CH	49.2, CH	47.8, CH	54.5, CH
10	44.2, qC	35.4, qC	43.8, qC	35.0, qC	46.1, qC
11	16.4, CH ₂	16.7, CH ₂	16.5, CH ₂	17.6, CH ₂	106.5, qC
12	29.0, CH ₂	29.2, CH ₂	31.5, CH ₂	32.0, CH ₂	170.0, qC
13	39.3, qC	39.5, qC	39.2, qC	45.8, qC	93.3, qC
14	56.0, qC	55.0, qC	56.1, qC	48.9, qC	92.6, qC
15	34.8, CH ₂	35.6, CH ₂	34.8, CH ₂	43.9, CH ₂	81.9, CH
16	81.6, CH	82.5, CH	81.6, CH	76.9, CH	28.9, CH ₂
17	57.7, CH	57.9, CH	56.2, CH	57.4, CH	48.0, CH
18	21.3, CH ₃	21.5, CH ₃	21.4, CH ₃	23.1, CH ₃	25.7, CH ₃
19	14.0, CH ₃	12.4, CH ₃	13.5, CH ₃	12.7, CH ₃	71.0, CH ₂
20	45.2, CH	44.7, CH	45.4, CH	41.1, CH	91.7, qC
21	180.1, qC	180.5, qC	179.2, qC	181.7, qC	105.9, CH
22	29.2, CH ₂	23.8, CH ₂	28.5, CH ₂	34.7, CH ₂	105.5, CH
23	26.0, CH ₂	34.7, CH ₂	126.9, CH	76.0, CH	146.7, CH
24	123.2, CH	201.1, qC	137.2, CH	121.7, CH	
25	132.9, qC	144.2, qC	81.8, qC	140.1, qC	
26	17.9, CH ₃	125.1, CH ₂	24.5, CH ₃	25.7, CH ₃	
27	25.7, CH ₃	17.6, CH ₃	24.1, CH ₃	18.3, CH ₃	
28	27.9, CH ₃	24.4, CH ₃	25.1, CH ₃	27.7, CH ₃	76.0, CH ₂
29	21.4, CH ₃	21.4, CH ₃	21.6, CH ₃	21.5, CH ₃	18.4, CH ₃
30	29.7, CH ₃	32.2, CH ₃	29.6, CH ₃	24.4, CH ₃	17.4, CH ₃
11-OCH ₃					52.3, CH ₃
12-OCH ₃					52.7, CH ₃
OCOCH ₃					170.5, qC
O ¹⁸ COCH ₃					171.5, qC
O ¹⁹ COCH ₃					21.0, CH ₃
O ²⁰ COCH ₃					21.3, CH ₃

Fifteen known compounds were also isolated and identified as meliastatin 3,¹² kulonic acid,¹⁵ kulactone,^{10,11} sendanolactone,^{9,10} toosendanone A,¹⁶ dubione B,¹² 24-methylenecycloartenone,¹⁷ meliavinol,¹⁸ 12β,20(S)-dihydroxydammar-24-en-3-one,¹⁹ dammarendiol II 3-*O*-caffeate,²⁰ toosendanin,²¹ 1-tigloyl-3,20-diacetyl-

11-methoxymeliacarpinin,¹⁴ 2β,3β,4β-trihydroxypregn-16-one,⁷ 3β-hydroxypregn-5,17(20)-dien-16-one,⁶ and 5α,8α-epidioxyergosta-6,22-dien-3β-ol²² by comparison of their physical and spectroscopic data with those published in the literature.

Experimental Section

General Experimental Procedures. Melting points were obtained on an X-4 micro melting point apparatus and are uncorrected. Optical rotations were recorded on a Horiba SEPA-300 polarimeter. UV spectra were obtained using a Shimadzu UV-2401A spectrophotometer, and IR spectra were measured on a Tenor 27 spectrophotometer using KBr pellets. NMR spectra were acquired on Bruker DRX-500 or AV-400 spectrometers with TMS as the internal standard. Mass spectra were obtained on a VG Autospec-3000 spectrometer or an API QSTAR Pulsar 1 spectrometer. Column chromatography (CC) was performed on silica gel (200–300 mesh, Qingdao Marine Chemical Ltd., Qingdao, P. R. China), RP-18 gel (40–65 μm, Fuji Silysia Chemical Ltd., Japan), and Sephadex LH-20 (Pharmacia Fine Chemical Ltd., Sweden). Fractions were monitored by TLC, and spots were visualized by heating the silica gel plates sprayed with 10% H₂SO₄ in EtOH.

Plant Material. Bark of *M. azedarach* was collected in Kunming, Yunnan Province, P. R. China, in October 2007. The sample was identified by Dr. Chun-Xia Zeng. A voucher specimen (Luo 071012) has been deposited with the Herbarium of Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation. An EtOH extract of dried bark of *M. azedarach* (30 kg) was concentrated, and the aqueous solution was partitioned with EtOAc. The EtOAc extract (820 g) was subjected to silica gel CC eluted with CHCl₃–Me₂CO (from 1:0 to 0:1) to give seven fractions (1–7). Fraction 2 (80 g), subjected to silica gel CC eluted with petroleum ether–Me₂CO from 20:1 to 8:1, gave four subfractions (2a–2d). Subfraction 2a (10 g) was separated on a RP-18 column (MeOH–H₂O, 6:1), followed by silica gel CC eluting with petroleum ether–EtOAc (5:1), to yield **5** (5.0 mg). Fraction 3 (88.0 g) was subjected to silica gel CC eluted with petroleum ether–Me₂CO from 10:1 to 4:1, yielding five subfractions (3a–3e). Separation of 3a (6.5 g) and 3c (7.8 g) on RP-18 eluted with MeOH–H₂O from 8:1 to 4:1 yielded **4** (5.8 mg) and **7** (42.2 mg), respectively. Subfraction 3d (9.8 g) was separated on silica gel eluted with CHCl₃–Me₂CO (9:1) to give **3** (15.0 mg). Fraction 4 (9.8 g) was subjected to RP-18 CC eluted with MeOH–H₂O (3:1), leading to **8** (98.5 mg). Fraction 7 (50 g) was subjected to silica gel CC eluted with CHCl₃–MeOH (from

15:1 to 5:1), followed by the RP-18 CC (MeOH–H₂O from 3:1 to 1:1) and Sephadex LH-20 (MeOH), yielding **6** (2.5 mg), **1** (15.0 mg), and **2** (11.1 mg).

2,3-Seco-dicarboxypregn-17-en-16-one (1): colorless needles (MeOH); mp 254–255 °C; $[\alpha]_D^{20} -78.1$ (c 0.29, DMSO); UV (DMSO) λ_{\max} (log ϵ) 258 (3.79) nm; IR (KBr) ν_{\max} 3432, 1729, 1631 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) and ¹³C NMR (100 MHz, DMSO-*d*₆) data, see Table 3; HRESIMS: *m/z* 361.2016 [M – H]⁺ (calcd for C₂₁H₂₉O₅, 361.2014).

2 α ,3 β ,4 β ,18-Tetrahydroxypregn-5-en-16-one (2): colorless needles (MeOH); mp 183–184 °C; $[\alpha]_D^{20} -71.8$ (c 0.28, MeOH); IR (KBr) ν_{\max} 3444, 1639 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) and ¹³C NMR (100 MHz, CD₃OD) data, see Table 3; HRESIMS *m/z* 363.2158 [M – H]⁺ (calcd for C₂₁H₃₁O₅, 363.2171).

3 α ,16 β ,20,22-Tetrahydroxergosta-5,24(28)-diene (3): colorless needles (MeOH); mp 242–243 °C; IR (KBr) ν_{\max} 3415, 1639 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) and ¹³C NMR (100 MHz, DMSO-*d*₆) data, see Table 3; HRESIMS *m/z* 469.3300 (calcd for C₂₈H₄₆O₄Na, 469.3293).

3 α -Hydroxytirucalla-7,24(25)-dien-6-oxo-21,16-olide (4): colorless needles (MeOH); mp 203–204 °C; $[\alpha]_D^{20} -11.1$ (c 0.21, CHCl₃); UV (CHCl₃) λ_{\max} (log ϵ) 244 (4.74) nm; IR (KBr) ν_{\max} 3442, 1787, 1659, 1642 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) data, see Tables 1 and 2; HRESIMS *m/z* 491.3138 (calcd for C₃₀H₄₄O₄Na, 491.3137).

Tirucalla-7,25(26)-diene-3,24-dion-21,16-olide (5): colorless prisms (MeOH); mp 216–218 °C; $[\alpha]_D^{20} -48.2$ (c 0.52, CHCl₃); UV (CHCl₃) λ_{\max} (log ϵ) 240 (3.56) nm; IR (KBr) ν_{\max} 1777, 1707 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) data, see Tables 1 and 2; HRESIMS *m/z* 489.2965 (calcd for C₃₀H₄₂O₄Na, 489.2980).

25-Hydroperoxytirucalla-7,23(24)-diene-3,6-dion-21,16-olide (6): colorless prisms (Me₂CO); mp 197–198 °C; $[\alpha]_D^{20} -42.1$ (c 0.58, CHCl₃); UV (CHCl₃) λ_{\max} (log ϵ) 244 (4.79) nm; IR (KBr) ν_{\max} 3439, 1776, 1655 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) data, see Tables 1 and 2; HRESIMS *m/z* 533.2677 (calcd for C₃₀H₄₂O₆Cl, 533.2669).

16 β -Hydroxytirucalla-7,24(25)-diene-3-oxo-21,23-olide (7): colorless needles (MeOH); mp 233–234 °C; $[\alpha]_D^{20} -80.5$ (c 0.31, CHCl₃); IR (KBr) ν_{\max} 3442, 1737, 1705, 1630 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) data, see Tables 1 and 2; HRESIMS *m/z* 491.3134 (calcd for C₃₀H₄₄O₄Na, 491.3137).

3,20-Diacetoxy-11-methoxymeliacarpinin (8): colorless needles (MeOH); mp 249–251 °C; $[\alpha]_D^{20} -11.9$ (c 0.53, CHCl₃); IR (KBr) ν_{\max} 3486, 1748, 1612 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) data, see Tables 1 and 2; HRESIMS *m/z* 657.2522 (calcd for C₃₂H₄₂O₁₃Na, 657.2523).

X-ray crystallographic analysis of 2,3-seco-dicarboxypregn-17-en-16-one (1): C₂₁H₃₀O₅, *M* = 362.45; monoclinic, space group *P*2₁; *a* = 7.3394(12) Å, *b* = 12.818(2) Å, *c* = 20.414(3) Å, $\alpha = \beta = \gamma = 90.00^\circ$, *V* = 1920.4(5) Å³, *Z* = 4, *T* = 298(2) K, *d* = 1.254 g/cm³, $\lambda = 0.71073$ Å, *R*₁ = 0.0617 for 1267 observations with *I* > 2 σ (*I*), *wR*₂ = 0.1098 for all data. Crystallographic data for **1** have been deposited at Cambridge Crystallographic Data Center (deposition no. 747980).

Acknowledgment. The authors are grateful to the National Basic Research Program of China (973 program 2009CB522300), and State Key Laboratory of Phytochemistry and Plant Resources in West China (P2010-ZZ13) for partial financial support. The authors also thank Mr. M.-J. Xie of Yunnan University for the X-ray crystallographic determination.

Supporting Information Available: The 1D, 2D NMR and MS spectra of new compounds **1–8** and crystal data for **1** are available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) Editorial Committee of Flora of China, Chinese Academy of Science. In *Flora of China*; Science Press: Beijing, 1997; Vol. 43, pp 100–102.
- (2) Yunnan Institute of Materia Medica. In *Illustrated Handbook for Medicinal Materials from Nature in Yunnan*; Yunnan Science and Technology Press: Kunming, 2005; Vol. 3, p 248.
- (3) Chinese Pharmacopoeia Committee. In *Chinese Pharmacopoeia*; Chemical Industry Press: Beijing, 2005; Vol. 1, p 141.
- (4) Mahato, S. B.; Sahu, N. P.; Podder, G. *Sci. Cult.* **1987**, *53*, 29.
- (5) Vishnukanta; Rana, A. C. *Pharmacogn. Rev.* **2008**, *2*, 173–179.
- (6) Ilyukhina, T. V.; Kamernitzkii, A. V.; Voznesenskaya, I. I. *Tetrahedron* **1974**, *30*, 2239–2243.
- (7) Ketwaru, P.; Klass, J.; Tinto, W. F.; McLean, S.; Reynolds, W. F. *J. Nat. Prod.* **1993**, *56*, 430–431.
- (8) Bian, B.; Altena, I. A. v. *Aust. J. Chem.* **1998**, *51*, 1157–1166.
- (9) Ochi, M.; Kotsuki, H.; Tokoroyama, T.; Kubota, T. *Bull. Chem. Soc. Jpn.* **1977**, *50*, 2499–2500.
- (10) Faizi, S.; Wasi, A.; Siddiqui, B. S.; Naz, A. *Aust. J. Chem.* **2002**, *55*, 291–296.
- (11) Siddiqui, S.; Siddiqui, B. S.; Ghiasuddin; Faizi, S. *J. Nat. Prod.* **1991**, *54*, 408–415.
- (12) Pettit, G. R.; Numata, A.; Iwamoto, C.; Morito, H.; Yamada, T.; Goswami, A.; Clewlow, P. J.; Cragg, G. M.; Schmidt, J. M. *J. Nat. Prod.* **2002**, *65*, 1886–1891.
- (13) Kamperdick, C.; Lien, T. P.; Adam, G.; Sung, T. V. *J. Nat. Prod.* **2003**, *66*, 675–678.
- (14) Takeya, K.; Qiao, Z. S.; Hirobe, C.; Itokawa, H. *Phytochemistry* **1996**, *42*, 709–712.
- (15) Chiang, C. K.; Chang, F. C. *Tetrahedron* **1973**, *29*, 1911–1929.
- (16) Sang, Y. S.; Zhou, C. Y.; Lu, A. J.; Yin, X. J.; Min, Z. D.; Tan, R. X. *J. Nat. Prod.* **2009**, *72*, 917–920.
- (17) Jayasinghe, U. L. B.; Vithana, H. S. K.; Wannigama, G. P.; Fujimoto, Y. *Fitoterapia* **2001**, *72*, 594–595.
- (18) Zeng, L.; Gu, Z. M.; Fang, X. P.; Fanwick, P. E.; Chang, C. J.; Smith, D. L.; McLaughlin, J. L. *Tetrahedron* **1995**, *51*, 2477–2488.
- (19) Zhao, C. C.; Wang, J. H.; Li, W.; Sha, Y.; Li, X. *Chin. J. Med. Chem.* **2003**, *13*, 211–214.
- (20) Fuchino, H.; Satoh, T.; Tanaka, N. *Chem. Pharm. Bull.* **1995**, *43*, 1937–1942.
- (21) Shu, G. X.; Liang, X. T. *Hua Hsueh Hsueh Pao* **1980**, *38*, 196–198.
- (22) Yue, J. M.; Chen, S. N.; Lin, Z. W.; Sun, H. D. *Phytochemistry* **2001**, *56*, 801–806.

NP1000472